Barry PJ - Search Results

1

Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.

Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Barry PJ, et al. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665. N Engl J Med. 2021. PMID: 34437784 Free PMC article. Clinical Trial.

2

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.

Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM; AZLI Active Comparator Study Group. Assael BM, et al. J Cyst Fibros. 2013 Mar;12(2):130-40. doi: 10.1016/j.jcf.2012.07.006. Epub 2012 Sep 15. J Cyst Fibros. 2013. PMID: 22985692 Free article. Clinical Trial.

3

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.

Barry PJ, Plant BJ, Nair A, Bicknell S, Simmonds NJ, Bell NJ, Shafi NT, Daniels T, Shelmerdine S, Felton I, Gunaratnam C, Jones AM, Horsley AR. Barry PJ, et al. Chest. 2014 Jul;146(1):152-158. doi: 10.1378/chest.13-2397. Chest. 2014. PMID: 24522694

4

Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning.

Barry PJ, Ronan N, Plant BJ. Barry PJ, et al. Semin Respir Crit Care Med. 2015 Apr;36(2):287-98. doi: 10.1055/s-0035-1546821. Epub 2015 Mar 31. Semin Respir Crit Care Med. 2015. PMID: 25826594 Review.

5

Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?

Jones AM, Barry PJ. Jones AM, et al. Among authors: barry pj. Thorax. 2015 Jul;70(7):615-6. doi: 10.1136/thoraxjnl-2015-207369. Thorax. 2015. PMID: 26071414 No abstract available.

6

New and Emerging Treatments for Cystic Fibrosis.

Barry PJ, Jones AM. Barry PJ, et al. Drugs. 2015 Jul;75(11):1165-75. doi: 10.1007/s40265-015-0424-8. Drugs. 2015. PMID: 26091951 Review.

7

Relationship between pulmonary hyperinflation and dyspnoea severity during acute exacerbations of cystic fibrosis.

Nicholson TT, Barry PJ, Waterhouse DF, Nolan GM, McKone EF, Gallagher CG. Nicholson TT, et al. Among authors: barry pj. Respirology. 2017 Jan;22(1):141-148. doi: 10.1111/resp.12885. Epub 2016 Sep 11. Respirology. 2017. PMID: 27614791

8

CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.

Mitchell RM, Jones AM, Barry PJ. Mitchell RM, et al. Among authors: barry pj. Paediatr Respir Rev. 2018 Jun;27:6-8. doi: 10.1016/j.prrv.2018.04.003. Epub 2018 Apr 25. Paediatr Respir Rev. 2018. PMID: 30158080 Review.

9

After the Celebrations: Lessons from the New Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy.

Barry PJ, Jones AM. Barry PJ, et al. Ann Am Thorac Soc. 2019 Feb;16(2):189-190. doi: 10.1513/AnnalsATS.201810-664ED. Ann Am Thorac Soc. 2019. PMID: 30707058 No abstract available.

10

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.

Bell SC, Barry PJ, De Boeck K, Drevinek P, Elborn JS, Plant BJ, Minić P, Van Braeckel E, Verhulst S, Muller K, Kanters D, Bellaire S, de Kock H, Geller DE, Conrath K, Van de Steen O, van der Ent K. Bell SC, et al. Among authors: barry pj. J Cyst Fibros. 2019 Sep;18(5):700-707. doi: 10.1016/j.jcf.2019.04.014. Epub 2019 May 3. J Cyst Fibros. 2019. PMID: 31056441 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

90 results

Search Page